Smruthi Organics Gets "Attestation of Inspection" from European Regulator after Solapur, India Unit Inspection

MT Newswires Live03-04 10:48

Smruthi Organics (BOM:540686) has received an "attestation of inspection" from the European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, after the inspection of its active pharmaceutical ingredient (API) manufacturing facility, Unit II in Solapur in Maharashtra, India.

The regulator had inspected the Solar unit from Aug. 27, 2025, to Aug. 29, 2025, and the attestation marks the closure of the EDQM inspection process, according to a BSE filing on Wednesday.

The company said the positive inspection outcome is expected to support its business expansion, improve customer confidence, and create additional opportunities in regulated export markets.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment